Literature DB >> 8592618

Efficacy of oral citrate administration in primary hyperoxaluria.

E Leumann1, B Hoppe, T Neuhaus, N Blau.   

Abstract

Urinary citrate is a potent inhibitor of calcium oxalate (CaOx) crystallization, but oral citrate has rarely been used in patients with primary hyperoxaluria (PH). We studied the effect of sodium citrate administration (0.1-0.15 g/kg/day) on urinary citrate excretion and CaOx saturation in seven paediatric patients and the clinical response to long-term treatment (average 4 years) in five patients. Urinary citrate increased from 0.73 to 2.54 mmol/24 h/1.73 m2 and urinary saturation for CaOx (calculated by equil 2) decreased from 11.41 to 6.79 (for both, p < 0.02). Long-term administration of alkali citrate [0.15 g (0.5 mmol)/kg/day] resulted in stable or improved renal function in three and slow deterioration in two partially non-compliant patients. Alkali citrate is effective in patients with PH.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592618     DOI: 10.1093/ndt/10.supp8.14

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  15 in total

Review 1.  [Evidence-based pharmacological metaphylaxis of stone disease].

Authors:  M Straub; R E Hautmann
Journal:  Urologe A       Date:  2006-11       Impact factor: 0.639

2.  Problems in the investigation of urine from patients suffering from primary hyperoxaluria type 1.

Authors:  N Laube; B Hoppe; A Hesse
Journal:  Urol Res       Date:  2005-09-08

Review 3.  Primary hyperoxalurias: diagnosis and treatment.

Authors:  Efrat Ben-Shalom; Yaacov Frishberg
Journal:  Pediatr Nephrol       Date:  2014-12-18       Impact factor: 3.714

4.  Metabolic profile and impact of diet in patients with primary hyperoxaluria.

Authors:  Roswitha Siener; Bernd Hoppe; Patricia Löhr; Stefan C Müller; Stefan Latz
Journal:  Int Urol Nephrol       Date:  2018-07-23       Impact factor: 2.370

5.  Excellent renal function and reversal of nephrocalcinosis 8 years after isolated liver transplantation in an infant with primary hyperoxaluria type 1.

Authors:  Mónica Galanti; Angélica Contreras
Journal:  Pediatr Nephrol       Date:  2010-07-14       Impact factor: 3.714

Review 6.  The role of preemptive liver transplantation in primary hyperoxaluria type 1.

Authors:  Markus J Kemper
Journal:  Urol Res       Date:  2005-11-13

7.  Does citrate prevent nephrocalcinosis in preterm neonates?

Authors:  Eveline A Schell-Feith; Aukje Moerdijk; Paul H T van Zwieten; Harmine M Zonderland; Herma C Holscher; Joana Kist-van Holthe; Bert J van der Heijden
Journal:  Pediatr Nephrol       Date:  2006-10-13       Impact factor: 3.714

8.  Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy.

Authors:  Jérôme Harambat; Karlijn J van Stralen; Laura Espinosa; Jaap W Groothoff; Sally-Anne Hulton; Rimante Cerkauskiene; Franz Schaefer; Enrico Verrina; Kitty J Jager; Pierre Cochat
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

9.  A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria.

Authors:  Bernd Hoppe; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2003-08-15       Impact factor: 3.714

10.  Sodium citrate inhibits the proliferation of human gastric adenocarcinoma epithelia cells.

Authors:  Yuan Xia; Xulong Zhang; Agula Bo; Juan Sun; Minhui Li
Journal:  Oncol Lett       Date:  2018-02-23       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.